Skip to main content
profile image
Selected Works of John M. Pagel, MD, PhD
Article
Second Interim Analysis of a Phase 3 Study Evaluating Idelalisib and Rituximab for Relapsed Chronic Lymphocytic Leukemia
Clinical Lymphoma, Myeloma & Leukemia (2015)
  • John M. Pagel, Fred Hutchinson Cancer Research Center
  • Steven E. Coutre, Stanford University
  • Richard R. Furman, Cornell University
  • Jeff P. Sharman, Cancer Institute
  • Bruce D. Cheson, Georgetown University Medical Center
  • Peter Hillmen, Leeds Teaching Hospitals NHS Trust
  • Jacqueline C. Barrientos, Hofstra University
  • Andrew D. Zelenetz, Memorial Sloan Kettering Cancer Center
  • Thomas J. Kipps, University of California, San Diego
  • Ian W. Flinn, Sarah Cannon Research Institute
  • Paolo Ghia, Vita-Salute San Raffaele University
  • Herbert A. Eradat, University of California, Los Angeles
  • Thomas Ervin, Harvard University
  • Nicole Lamanna, Columbia University Medical Center
  • Bertrand Coiffier, University of Lyon
  • Andrew Pettitt, University of Liverpool
  • Xiaoming Li
  • Thomas M. Jahn, Children's Hospital Los Angeles
  • Susan M. O’Brien, University of Texas MD Anderson Cancer Center
  • Michael J. Hallek, University of Cologne
Link
Disciplines
Publication Date
January 6, 2015
DOI
10.1016/j.clml.2015.04.062
Citation Information
John M. Pagel, Steven E. Coutre, Richard R. Furman, Jeff P. Sharman, et al.. "Second Interim Analysis of a Phase 3 Study Evaluating Idelalisib and Rituximab for Relapsed Chronic Lymphocytic Leukemia" Clinical Lymphoma, Myeloma & Leukemia Vol. 15 (2015)
Available at: http://works.bepress.com/john-pagel/77/